Kalaris Therapeutics

KLRSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$96.835 M

$4.07 -2.86%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$43.4M

Loss-making

Shares outstanding

22,928,303

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#112Black Diamond TherapeuticsBDTX$112.0M
#113Pelthos TherapeuticsPTHS$98.6M
#114Kalaris TherapeuticsKLRS$96.8M
#115Cognition TherapeuticsCGTX$96.7M
#116Cardiff OncologyCRDF$77.2M

Where these numbers come from

Share counts and financials for Kalaris Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.